Edition:
United States

Dermira Inc (DERM.OQ)

DERM.OQ on NASDAQ Stock Exchange Global Select Market

26.18USD
23 Feb 2018
Change (% chg)

$-0.56 (-2.09%)
Prev Close
$26.74
Open
$26.90
Day's High
$27.55
Day's Low
$25.41
Volume
386,167
Avg. Vol
159,907
52-wk High
$38.75
52-wk Low
$21.39

Chart for

About

Dermira, Inc. is a biopharmaceutical company. The Company is focused on the development of therapeutic solutions in medical dermatology to treat skin conditions, such as hyperhidrosis, psoriasis and acne. Its portfolio includes three late-stage product candidates: Cimzia (certolizumab pegol), glycopyrronium tosylate and... (more)

Overall

Beta: 0.84
Market Cap(Mil.): $1,091.03
Shares Outstanding(Mil.): 41.67
Dividend: --
Yield (%): --

Financials

  Industry Sector
P/E (TTM): -- 195.87 16.59
EPS (TTM): -- -- --
ROI: -- -0.71 35.07
ROE: -- -3.37 17.79

BRIEF-Dermira Qtrly Loss Per Share $‍1.34​

* DERMIRA REPORTS FOURTH QUARTER AND FULL YEAR 2017 FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE

Feb 22 2018

BRIEF-Dermira posts Q3 loss $4.30/shr, says FDA accepts NDA for glycopyrronium tosylate

* Dermira reports third quarter 2017 financial results and announces that FDA accepts new drug application for glycopyrronium tosylate for the treatment of patients with primary axillary hyperhidrosis

Nov 06 2017

BRIEF-Dermira and UCB agree to end collaboration agreement for Cimzia

* Dermira and UCB agree to end collaboration agreement for Cimzia

Nov 06 2017

BRIEF-Dermira highlights new long-term safety data for glycopyrronium tosylate

* Dermira highlights new long-term safety data for glycopyrronium tosylate in primary axillary hyperhidrosis at fall clinical dermatology conference

Oct 13 2017

BRIEF-Dermira completes patient enrollment in two phase 3 trials of olumacostat glasaretil for the treatment of acne vulgaris

* Dermira completes patient enrollment in two phase 3 pivotal trials of olumacostat glasaretil for the treatment of acne vulgaris

Oct 05 2017

BRIEF-Dermira presents new data showing impact of primary axillary hyperhidrosis on patients

* Dermira -‍ presented new patient-reported outcomes data from two Phase 3 clinical trials showing impact of primary axillary hyperhidrosis on patients​

Sep 13 2017

Competitors

Earnings vs. Estimates